Prognostic Value of Different Iron Status Definitions in Congestive Heart Failure: A Retrospective MIMIC-IV Analysis of Risk Stratification and Mortality

Abdulla Hourani[1], MD, Medical University of Warsaw
https://orcid.org/0000-0001-9619-381X

Arman David Sürmeli[2], Medical University of Warsaw
https://orcid.org/0009-0006-4934-4391

Sai Keertana Devarapalli[3], Medical University of Warsaw
https://orcid.org/0009-0000-1098-3811

Abstract

Introduction: Iron deficiency (ID) is prevalent in congestive heart failure (CHF), worsening outcomes. While European guidelines recommend screening using ferritin and transferrin-saturation (TSAT), inconsistent diagnostic criteria, especially regarding functional ID (ferritin 100-299 µg/L + TSAT <20%) and hyperferritinemia, limit prognostic accuracy.

Aim: This study evaluated iron status definitions, including guideline criteria and a combined Ferritin-TSAT model, for predicting 365-day mortality in hospitalized CHF patients.

Methods: This retrospective analysis used MIMIC-IV data from 1,839 CHF patients. Iron status within 24h of admission was categorized using: 1) Guideline ID vs. non-ID; 2) Ferritin tertiles; 3) TSAT tertiles; 4) Combined Ferritin-TSAT model (Low: guideline ID; Intermediate: ferritin 100-299 + TSAT ≥20%; High: ferritin ≥300 µg/L). Adjusted Cox models assessed mortality associations.

Results: Guideline ID (33.65% prevalence) strongly associated with higher 1-year mortality (56.1% vs. 29.4%; adjusted HR 4.36, 95%CI 3.35-5.34). The combined Ferritin-TSAT model showed significant prognostic value, differentiating true ID (reference) from hyperferritinemia (adjusted HR 0.50 vs. ID) and intermediate group (adjusted HR 0.36 vs. ID), indicating varying risk relative to the most deficient group. This combined model better distinguished hyperferritinemic and iron-replete subgroups than the binary guideline definition.

Conclusion: Iron status, including deficiency and hyperferritinemia, independently predicts 1-year mortality in CHF. While guideline ID is a strong predictor, a combined Ferritin-TSAT classification offers finer risk stratification by identifying distinct phenotypes (true deficiency, hyperferritinemia, intermediate). Nuanced iron-status assessment could improve prognostic evaluation and guide personalized therapies (e.g., IV iron for deficiency, investigation for hyperferritinemia) to enhance CHF outcomes. Prospective validation is needed.

Introduction

Iron deficiency (ID) anemia is a significant global public health concern and affects a substantial proportion of patients with congestive heart failure (CHF), with estimates suggesting that as many as 34–63% of individuals with chronic heart failure may be iron deficient [1]. ID itself can adversely influence outcomes, by contributing to poor exercise tolerance, diminished health-related quality of life, and increased risks of hospitalization and mortality, even in the absence of anemia [2,3]. Recognizing the central role of ID in exacerbating congestive heart failure symptoms, the European Society of Cardiology has formally acknowledged iron deficiency as an important comorbidity and now recommends routine testing of iron status, including transferrin saturation (TSAT) and serum ferritin, for all newly diagnosed heart failure patients [4].

ID in CHF patients can manifest as either absolute iron deficiency (depleted iron stores) or functional iron deficiency (adequate iron stores that cannot be effectively mobilized). Functional iron deficiency occurs when inflammatory processes in heart failure trigger increased production of hepcidin, which blocks iron release from storage sites despite normal or elevated ferritin levels. [5,6] This creates a state where iron is unavailable for critical cellular processes despite being present in the body [7,8]. The prevailing consensus holds that ID, irrespective of anemia, directly contributes to heart failure pathophysiology by impairing mitochondrial energy production, driving maladaptive cardiac remodeling, and activating inflammatory pathways that collectively reduce cardiac output [9].

Multiple large-scale trials and meta-analyses have consistently highlighted the clinical benefits of correcting iron deficiency in CHF. In particular, intravenous (IV) iron supplementation—most notably ferric carboxymaltose—has been shown to alleviate symptoms, improve exercise capacity, and reduce heart failure–related hospitalizations [4,10,11,12]. Observational and randomized evidence further indicate that these advantages extend beyond anemic patients to those with normal hemoglobin levels but low TSAT (<20%), which nonetheless signals depleted functional iron stores. IV iron administration improves left ventricular function indices, enhances functional status as measured by 6-minute walk tests, and reduces the rate of cardiovascular (CV) death or readmission for worsening congestive heart failure [10,13]. Oral iron supplementation, on the other hand, has generally not demonstrated consistent benefits in CHF, largely due to poor absorption and intolerability in this population [9]. This distinction reflects the necessity of targeting iron deficiency—guided by iron parameters like TSAT and ferritin—as a central therapeutic strategy in heart failure, rather than relying on hemoglobin levels to dictate treatment decisions.

However, the clinical utility of these findings is hindered by inconsistent diagnostic criteria, as there remains no universally accepted definition of iron deficiency in CHF for mortality prediction. Cutoff values for ferritin and TSAT vary among studies, with recent studies advocating for sole TSAT oriented operational definitions [14,15], creating a lack of standardization that complicates the analysis of ID prevalence, influencing patient therapy outcomes [1]. Current recommendations published on the European Society of Cardiology (2016) attempt to address this by defining iron deficiency in heart failure patients as serum ferritin of <100 μg/L, considered absolute iron deficiency, or serum ferritin 100–299 μg/L with a TSAT <20%, considered functional iron deficiency [4,17,18]. Despite ESC guidance, the prognostic validity of these thresholds for long-term, post-discharge mortality remains unclear.

In light of the above, this study focuses on further clarifying the effects and optimal diagnostic criteria in prognosis of iron deficiency in congestive heart failure. By examining the impact of ID on long-term mortality beyond the acute hospital setting, this research aims to address the

ongoing need for clearer, evidence-based guidelines on screening and treating ID in CHF. To this end, the study rigorously evaluates and compares different stratification approaches, including a refined combined model, to overcome limitations in current definitions. Ultimately, these insights may contribute to improved quality of life and reduce the significant burden of recurrent hospitalizations and mortality among heart failure patients worldwide.

Methodology

Study Design and Setting

A retrospective observational study design was implemented, focusing on adult patients with CHF over the course of a year. Electronic medical record (EMR) data, clinical notes, and laboratory values were extracted and merged for analysis. Admissions were included if International Classification of Diseases (ICD-9/10) documentation confirmed CHF (supported by clinical notes or imaging), iron testing (ferritin, iron, total iron-binding capacity (TIBC), or TSAT) and laboratory tests was performed within 24 hours of admission, and only the first hospitalization was retained for patients with multiple admissions.

Patient Selection

Inclusion criteria were met by 1839 patients aged >18 and <89 years, with validated ICD diagnoses of CHF and accessible iron parameter measurements within the first 24 hours, analysing a large, granular critical-care cohort extracted from the Medical Information Mart for Intensive Care IV (MIMIC-IV 2.2) database, a public database from the Beth Israel Deaconess Medical Center, containing electronic health records on patients admitted between 2008 and 2019.

Clinical notes were analyzed using ClinicalBERT [16], a transformer-based language model pre-trained on clinical notes from MIMIC-III, supported by regex-based methods to extract and verify CHF diagnoses and ejection fraction categories from discharge notes. Demographic and clinical variables (e.g., age, sex, comorbidities including shock, malignancy, renal disease, as well as ICU stay and ejection fraction status) were collected from structured EMR fields and supplemented by natural language processing. Laboratory measurements for ferritin, iron, TIBC, TSAT, hemoglobin, and other routine labs (e.g., creatinine for eGFR calculation) were obtained from the first tests within 24 hours of admission, in consistency with previous studies.

Definition of Iron Deficiency

Iron deficiency (ID) was defined using guideline-based thresholds of ferritin <100 μg/L or ferritin 100–299 μg/L with TSAT <20% [17].

Data Cleaning and Categorization

All relevant continuous variables underwent rigorous normality assessment using the Anderson-Darling test for skewness and kurtosis, the Kolmogorov-Smirnov test for distribution comparisons, and visual inspection of histograms and Q-Q plots. Missing data were found to be not missing at random (NMAR) based on Little's MCAR test and were therefore excluded.

Patients were categorized based on guideline-defined ID versus non-ID, clinically defined Ferritin tertile category, TSAT tertile category, and a combined Ferritin-TSAT tertile category classification. Given this study's focus on mortality prediction, evaluating the prognostic utility of iron deficiency definitions was prioritized over distinguishing between functional and absolute subtypes, as clinical guidelines and prior evidence emphasize iron parameters' collective role in risk stratification [8]. Clinically, ferritin levels were classified as low if below 100 μg/L, intermediate between 100 μg/L and 299 μg/L, and high if above 300 μg/L. TSAT levels were considered very low if below 10%, low between 10% and 20%, and normal if above 20% [19]. The combined Ferritin-TSAT classification defined low iron status as ferritin below 100 μg/L or between 100 μg/L and 299 μg/L with TSAT below 20%, intermediate as ferritin between 100 μg/L and 299 μg/L with TSAT above 20%, and high as ferritin above 300 μg/L. This classification framework was used to

explore how variations in iron parameters relate to clinical outcomes while considering iron deficiency and overload.

Statistical Analyses

Statistical analyses were conducted to compare differences across groups, with the choice of parametric (t-tests, ANOVA) or nonparametric (Wilcoxon, Kruskal–Wallis) tests determined by distributional assessments. Categorical variables were compared using chi-square tests or Fisher's exact test, depending on expected cell counts. Summary statistics for continuous variables were reported as means with standard deviations (SD) for normally distributed data or medians with interquartile ranges (IQR) for skewed distributions, while categorical variables were expressed as frequencies and percentages.

For time-to-event analysis, Kaplan–Meier survival curves were generated to visualize differences in 365-day mortality across study groups. Log-rank tests were performed to assess statistical significance between survival curves. To further quantify the association between iron parameters and mortality, Cox proportional hazards models were employed to estimate hazard ratios (HRs) with 95% confidence intervals (CIs). The proportional hazards assumption was evaluated using Schoenfeld residuals. Crude and adjusted cox proportional hazards models were employed to estimate hazard ratios (HRs) with 95% confidence intervals (CIs).

To account for potential confounders, three progressively adjusted Cox models were constructed for each classification framework. Model 1 adjusted for age, sex, ICU admission, and ejection fraction category, accounting for basic demographic and clinical severity factors. Model 2 built upon Model 1 by additionally adjusting for cardiac arrest, hypertension, diabetes, shock, malignancy, hemoglobin, and estimated glomerular filtration rate (eGFR) to incorporate comorbid conditions and laboratory markers relevant to both iron metabolism and cardiovascular outcomes. Model 3 further adjusted for dialysis, percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG), beta blockers, angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARBs), and iron supplementation, allowing for a comprehensive evaluation of treatment-related influences on mortality.

Subgroup analyses were performed on categories of: age ≥65 versus <65, sex, and reduced vs.. preserved ejection fraction to assess additional adjustments for potential confounding variables. Statistical significance was set at $P < 0.05$, and all analyses were performed using R (version 4.3).

Ethical Considerations

The dataset was de-identified, and informed consent was waived by the institutional review board due to the retrospective nature of the analysis. All data handling, analysis, and natural language processing were performed securely on a local server.

Results

A total of 1,839 unique index admissions with confirmed congestive heart failure fulfilled all prespecified eligibility criteria. Marked imbalances in baseline characteristics were observed between iron-deficient and non-deficient patients, and are summarised in **Table 1**. Iron deficient patients were older (median 77.0 [IQR 18.0] vs. 72.0 [18.0] years) and more frequently female (49.6% vs. 35.3%) (both P < 0.001). Laboratory contrasts included markedly lower ferritin (median 71.0 vs. 392.50 µg/L), iron (31.00 vs. 45.00 µg/dL) and TSAT (9.6% vs. 19.9%), but higher TIBC and transferrin (all P < 0.001). Clinically, they had fewer admissions for surgical interventions, shorter hospital stays and lower prevalence of shock (15% vs. 25%), acute kidney injury (14% vs. 26%), and myocardial infarction (14% vs. 23%), yet higher rates of atrial fibrillation (53% vs. 46%) and valvulopathies (49% vs. 36%). Iron-deficient patients had higher anticoagulant (51.4% vs. 40.1%) and iron supplementation use (50.7% vs. 17.9%), but lower vasopressor (20.8% vs. 36.1%), heparin (76.7% vs. 87.7%), and ACEi/ARB exposure (28.8% vs. 32.5%) (all p < 0.001 except ACEi/ARB: p = 0.109). During multivariable analysis, older age, ICU admission, shock, coronary-artery disease, diabetes, and solid malignancy were independently associated with higher 365-day mortality, whereas prior CABG, ACE-inhibitor/ARB therapy, beta-blocker use, and intravenous iron supplementation each conferred a significant protective effect (all P < 0.05) *(Supplementary Materials S1–4)*.

Variable	Non-Iron deficiency (n= 1220)	Iron deficiency (n= 619)	P-value
Demographics			
Age	72.00 (18.00)	77.00 (18.00)	<0.001
Gender (f)	431 (35.3%)	307 (49.6%)	<0.001
Race			
			0.241
White	812 (66.6%)	435 (70.3%)	
Asian	33 (2.7%)	8 (1.3%)	
Hispanic	59 (4.8%)	29 (4.7%)	
Black	23 (1.9%)	9 (1.5%)	
Mixed/Other	293 (24.0%)	138 (22.3%)	
Marital status			
			0.241
Married	812 (66.6%)	435 (70.3%)	
Widowed	33 (2.7%)	8 (1.3%)	
Divorced	59 (4.8%)	29 (4.7%)	
Single	23 (1.9%)	9 (1.5%)	
Other	293 (24.0%)	138 (22.3%)	
Hospitalization			
Surgical admission	138 (11.3%)	28 (4.5%)	<0.001
Hospital LOS	8.94 (8.58)	6.98 (7.80)	<0.001
ICU stay	698 (57.2%)	211 (34.1%)	<0.001

ICU LOS	1.14 (3.87)	0.00 (1.21)	<0.001
Laboratory			
Troponin	0.11 (0.32)	0.07 (0.16)	<0.001
Ferritin	392.50 (515.75)	71.00 (74.00)	<0.001
Iron	45.00 (45.00)	31.00 (22.00)	<0.001
TIBC	234.00 (89.00)	332.00 (110.50)	<0.001
Transferrin	180.00 (68.00)	255.00 (84.50)	<0.001
TSAT	19.91 (15.72)	9.64 (7.33)	<0.001
Hemoglobin	10.10 (3.50)	9.20 (2.70)	<0.001
Hematocrit	31.17 (10.39)	29.70 (8.14)	<0.001
RBC	3.43 (1.18)	3.46 (1.00)	0.288
RDW	15.30 (2.90)	16.60 (3.53)	<0.001
Platelets	189.00 (112.00)	211.00 (110.00)	<0.001
Glucose	143.00 (83.00)	139.00 (84.00)	0.187
Creatinine	1.60 (1.60)	1.50 (1.10)	<0.001
eGFR	44.93 (49.16)	46.64 (41.99)	0.004
Ejection fraction	40.00 (25.00)	40.00 (25.00)	0.635
CKD-EPI Group			<0.001
1	148 (12.1%)	79 (12.8%)	
2	260 (21.3%)	141 (22.8%)	
3	400 (32.8%)	250 (40.4%)	
4	241 (19.8%)	118 (19.1%)	
5	168 (13.8%)	29 (4.7%)	
Ejection fraction Group			0.201
<40	442 (36.2%)	360 (58.2%)	
41-49	60 (4.9%)	44 (7.1%)	
>50	545 (44.7%)	388 (62.7%)	
Comorbidities			
STEMI	32 (2.6%)	4 (0.6%)	0.007
NSTEMI	254 (20.8%)	84 (13.6%)	<0.001
Cardiac arrest	39 (3.2%)	8 (1.3%)	0.022
Valvulopathies	434 (35.6%)	304 (49.1%)	<0.001
Mitral valve disease	249 (20.4%)	168 (27.1%)	0.001
Atrial valve disease	174 (14.3%)	118 (19.1%)	0.009
Atrial fibrillation	559 (45.8%)	330 (53.3%)	0.003

Hypertension	989 (81.1%)	522 (84.3%)	0.096
Hyperlipidemia	68 (5.6%)	27 (4.4%)	0.318
Peripheral vascular disease	335 (27.5%)	175 (28.3%)	0.755
Diabetes	591 (48.4%)	319 (51.5%)	0.229
Chronic kidney failure	631 (51.7%)	322 (52.0%)	0.943
Acute kidney failure	315 (25.8%)	88 (14.2%)	<0.001
Mild liver disease	124 (10.2%)	58 (9.4%)	0.648
Severe liver disease	43 (3.5%)	17 (2.7%)	0.454
Malignant cancer	121 (9.9%)	49 (7.9%)	0.188
Obesity	182 (14.9%)	129 (20.8%)	0.002
Alcoholism	225 (18.4%)	73 (11.8%)	<0.001
Shock	309 (25.3%)	90 (14.5%)	<0.001
History of PCI	1025 (84.0%)	517 (83.5%)	0.001
History of CABG	179 (14.7%)	112 (18.1%)	0.067
History of major CV event	195 (16.0%)	124 (20.0%)	0.036
Medications			
Antiplatelets	932 (76.4%)	445 (71.9%)	0.041
Aspirin	920 (75.4%)	430 (69.5%)	0.008
P2Y12 Inhibitors	298 (24.4%)	113 (18.3%)	0.003
Anticoagulants	489 (40.1%)	318 (51.4%)	<0.001
Heparin	1070 (87.7%)	475 (76.7%)	<0.001
Vasopressors	440 (36.1%)	129 (20.8%)	<0.001
ACEi	397 (32.5%)	178 (28.8%)	0.109
ARB	192 (15.7%)	106 (17.1%)	0.487
Beta blockers	1008 (82.6%)	499 (80.6%)	0.320
CCB	265 (21.7%)	113 (18.3%)	0.094
Statins	911 (74.7%)	466 (75.3%)	0.819
Antidiabetic	63 (5.2%)	38 (6.1%)	0.448
Iron supplement	218 (17.9%)	314 (50.7%)	<0.001
Iron supplement (IV)	81 (6.6%)	191 (30.9%)	<0.001
Iron supplement (PO)	154 (12.6%)	159 (25.7%)	<0.001
Procedures and Interventions			
CABG	66 (5.4%)	11 (1.8%)	<0.001
PCI	95 (7.8%)	22 (3.6%)	0.001
IABP	30 (2.5%)	10 (1.6%)	0.316
Mechanical support	49 (4.0%)	15 (2.4%)	0.104
Pacemaker	1090 (89.3%)	382 (61.7%)	<0.001

Implantable defibrillator	1077 (88.3%)	382 (61.7%)	<0.001
Valve surgery	61 (5.0%)	24 (3.9%)	0.334
Dialysis	120 (9.8%)	20 (3.2%)	<0.001
Ventilation	623 (51.1%)	175 (28.3%)	<0.001
Mortality			
14-day Mortality	93 (7.6%)	52 (8.4%)	0.622
28-day Mortality	149 (12.2%)	81 (13.1%)	0.646
90-day Mortality	231 (18.9%)	178 (28.8%)	<0.001
180-day Mortality	281 (23.0%)	243 (39.3%)	<0.001
365-day Mortality	359 (29.4%)	347 (56.1%)	<0.001
Hospital Mortality	108 (8.9%)	51 (8.2%)	0.723

Table 1. Baseline patient demographics, laboratory values, comorbidities, medications, procedures, and mortality outcomes stratified by iron deficiency status.

Within this cohort, guideline-defined iron deficiency anemia was present in 33.65% (N = 619), leaving 66.34% categorised as non-ID. Application of the composite Ferritin–TSAT scheme reclassified patients into true ID (50.4%), hyperferritinemia (40.4%), and iron-replete (9.2%) groups, illustrating appreciable overlap yet clear segregation between the binary and composite definitions. Overall out-of-hospital 365-day mortality was 38.4% (N = 706) with survival diverging sharply by iron status. Guideline-defined iron deficiency was associated with a crude one-year mortality of 56.1% compared with 29.4% among non-deficient patients (P < 0.001).

Throughout the four definition models, iron status retained a clear, independent association with 365-day mortality. Unadjusted survival analyses confirmed poorer outcomes with ID regardless of definition, with Kaplan–Meier curves illustrating survival for each definition displayed in **Figures 1–4**. Univariate analyses confirmed a strong crude, more than double mortality hazard association between guideline-defined ID and 365-day mortality (HR 2.48, 95%CI 2.09–2.94), whereas graded indices showed stepwise protection with rising ferritin (Ferritin Category Model: HR 0.49, 95%CI 0.39–0.60), or TSAT (TSAT Category Model: HR 0.72, 95%CI 0.65–0.81), or both (Ferritin-TSAT Category Model: HR 0.70, 95%CI 0.63–0.78) **(Table 2)**. After sequential, fully adjusted multivariate regression modeling for demographics, comorbidity and treatment, including age, sex, ICU stay, shock, malignancy, diabetes, renal function, hemoglobin, dialysis status, invasive procedures, and guideline-directed therapies (full list of covariates available in *Supplementary Materials*), these trends continued, as the Guidelines-based Model remained independently predictive with a 4.36-fold increase in 365-day mortality risk (95%CI 3.35–5.34), but lacked the granularity as seen in the tertile Ferritin–TSAT model, isolating hyperferritinemic and true non-ID phenotypes with HR 0.50 (95%CI 0.38–0.51) and HR 0.36 (95%CI 0.24–0.53), respectively. To note, in tertile models, HR < 1 indicates reduced mortality risk relative to the most iron-deficient group (reference), not absolute treatment benefit **(Table 2)**.

Iron Variable Model	Model 1	Model 2	Model 3	Univariate
Guidelines-based Model	**3.350** (95%CI 2.730–4.110), p<0.001	**3.787** (95%CI 3.053–4.697), p<0.001	**4.356** (95%CI 3.349–5.338), p<0.001	**2.48** (95%CI 2.09–2.94), p<0.001
TSAT Category Model	*Tertile 2: **0.753** (95%CI 0.610–0.930), p=0.009* *Tertile 3: **0.609** (95%CI 0.484–0.766), p<0.001*	*Tertile 2: **0.780** (95%CI 0.626–0.971), p=0.026* *Tertile 3: **0.625** (95%CI 0.492–0.794), p<0.001*	*Tertile 2: **0.804** (95%CI 0.644–1.003), p=0.053* *Tertile 3: **0.632** (95%CI 0.494–0.810), p<0.001*	**0.72** (95%CI 0.65–0.81), p<0.001
Ferritin Category Model	*Tertile 2: **0.671** (95%CI 0.544–0.827), p<0.001* *Tertile 3: **0.400** (95%CI 0.313–0.511), p<0.001*	*Tertile 2: **0.649 (**95%CI 0.523–0.804), p<0.001* *Tertile 3: **0.362** (95%CI 0.280–0.468), p<0.001*	*Tertile 2: **0.670** (95%CI 0.538–0.833), p<0.001* *Tertile 3: **0.308** (95%CI 0.234–0.404), p<0.001*	**0.49** (95%CI 0.39–0.60), p<0.001
Ferritin-TSAT Category Model	*Tertile 2: **0.337** (95%CI 0.228–0.496), p<0.001* *Tertile 3: **0.498** (95%CI 0.328–0.517), p<0.001*	*Tertile 2: **0.338** (95%CI 0.228–0.501), p<0.001* *Tertile 3: **0.551** (95%CI 0.389–0.622), p=0.001*	*Tertile 2: **0.356** (95%CI 0.238–0.530), p<0.001* *Tertile 3: **0.495** (95%CI 0.380–0.512), p<0.001*	**0.70** (95%CI 0.63–0.78), p<0.001

Table 2. Hazard ratios and confidence intervals for iron deficiency regressions across multiple crude and adjusted multivariate and univariate models. Tertile models encompass multiple values as they categorize data into three distinct groups and HR<1 reflects comparison with a profoundly iron-deficient reference group, not absolute benefit.

Model discrimination was satisfactory and subgroup analyses confirmed stable performance with minimal variation in hazard estimates within demographic and clinical strata (Ferritin-TSAT Category Model: age ≥65 vs. <65, sex, and mildly-reduced, reduced vs. preserved ejection fraction, all $P < 0.05$, except HFmrEF (in Tertile 2: p=0.151 & Tertile 3: p=0.219)). The choice of 65 years as an age cutoff during subgroup analysis aligned with standard cardiology prediction recommendations.

Discussion

This study demonstrates that iron dysregulation in CHF—spanning deficiency to hyperferritinemia—serves as a significant prognostic indicator of one-year survival. By evaluating novel categorizations of ID, we move beyond binary classifications to identify distinct risk phenotypes. Among the tested categorical frameworks, and as outlined in **Table 2**, the guideline-based definition provided superior risk stratification for adverse outcomes in high-risk patients during multivariate hazard analysis, while the combined Ferritin-TSAT model revealed an iron store subgroup with markedly reduced mortality risk.

The prognostic implications of iron deficiency and hyperferritinemia in hospitalized CHF patients are profound; a study of 1506 CHF patients identified ID as a strong and independent predictor of mortality (HR 1.42, 95%CI 1.14–1.77, $P = 0.002$) [1]. A stark mortality gradient emerged between ID and non-ID cohorts (56.1% vs. 29.4% at one year $P < 0.001$), highlighting iron homeostasis as pivotal to cardiac and systemic function. Notably, Kaplan–Meier analyses underscored key distinctions among models (all $P < 0.001$): while guideline-based classifications exhibited the strongest survival divergence overall **(Figure 1)**, they—alongside TSAT- and ferritin-only models **(Figures 2, 3)**—showed limited prognostic utility within the first 30 days. In contrast, the Ferritin-TSAT model **(Figure 4)** demonstrated sustained late-term yet stronger early term stratification, distinguishing "true" non-ID patients, the intermediate subgroup, from the two high-risk subgroups. For reference, iron deficiency in the Ferritin-TSAT model showed a consistent survival pattern due to its fixed, guideline-definition across these analyses.



Figure 1. 365-day Kaplan-Meier survival curve on iron deficiency anemia based on current guideline definitions.



Figure 2. 365-day Kaplan-Meier survival curve on iron deficiency anemia based on a TSAT category model. Group 1 (TSAT <10%), Group 2 (TSAT 10-20%), and Group 3 (TSAT ≥20%).



Figure 3. 365-day Kaplan-Meier survival curve on iron deficiency anemia based on a Ferritin category model. Group 1 (ferritin <100 µg/L), Group 2 (ferritin 100–299 µg/L), and Group 3 (ferritin >300 µg/L).



Figure 4. 365-day Kaplan-Meier survival curve on iron deficiency anemia based on a Ferritin-TSAT category model. Group 1 (ferritin <100 µg/L or 100–299 µg/L + TSAT <20%), Group 2 (ferritin >300 µg/L), and Group 3 (ferritin 100–299 µg/L + TSAT ≥20%).

Current guideline criteria, though clinically practical, conflate hyperferritinemic (≥300 µg/L) and normoferritinemic patients under a single "non-deficient" label, obscuring inflammation- or congestion-driven ferritin and iron elevations [9, 18, 20, 21]. TSAT thresholds (<10%) effectively isolate severe functional deficiency but fail to discern elevated ferritin driven by said inflammation or congestion. Conversely, ferritin tertiles identify hyperferritinemia but overlook functional deficiency in patients with normal ferritin but critically low TSAT. The Ferritin-TSAT model addresses these gaps by delineating three phenotypes: (1) true deficiency (low ferritin/TSAT), (2) hyperferritinemia,

and (3) an intermediate-risk cohort. Studies show that patients with intermediate iron often fare better, substantiating the value of a combined biomarker approach for more precise patient stratification [20, 22, 23].

Short‑term prognostic results showed an immediate risk carried by severely deficient patients and some hyperferritinemic individuals, whereas long-term mortality confirmed that uncorrected iron dysregulation, be it deficiency or high ferritin, contributes to heart failure progression and mortality [9, 24]. By unmasking the prognostic and therapeutic relevance of iron dysregulation subtypes, this model suggests limitations of the current binary paradigm and could inform future clinical guidelines, which currently overlook this maldistribution as a modifiable risk factor. Because non‑binary criteria may highlight hyperferritinemic individuals, clinicians could better allocate iron therapy, whether that therapy involves supplementation or chelation. Thus, the adoption of these new categorizations, in conjunction with other pertinent clinical and laboratory measures, may allow for a more individualized approach to preventing adverse outcomes in CHF. For instance, the ACC/AHA and ESC guidelines for CHF management emphasize iron deficiency correction but lack criteria to address hyperferritinemia or guide differential workups. Integrating the Ferritin-TSAT model into future iterations would enable tailored management, aligning therapies with underlying pathophysiology [20, 25]: intravenous iron for true deficiency, diuresis or anti-inflammatories for congestion- or inflammation-mediated hyperferritinemia, and close monitoring for intermediate-risk patients .

Early iron parameter assessment (within 24 hours of admission) could identify high-risk patients prone to early decompensation, as both deficiency and hyperferritinemia correlate with rapid clinical decline. Multivariate analyses confirmed iron dysregulation’s independent mortality risk, unaffected by covariates such as shock, malignancy, or ICU admission. Importantly, standard CHF therapies (beta-blockers, ACE inhibitors/ARBs) synergize with iron status optimization. In patients with low ferritin or TSAT, especially below the accepted guideline thresholds, intravenous iron therapy appears to confer significant survival benefits, with hazard ratios suggesting protective effects [13]. Early repletion reduces 14–28-day mortality and may attenuate one-year risk, whereas hyperferritinemic patients—often misclassified as "non-deficient"—risk undertreatment.

Limitations

Several limitations warrant caution in interpreting these findings. The dataset is based on a retrospective review of records from a single center, Beth Israel Deaconess Medical Center, which may limit generalizability to other institutions or healthcare settings with different patient demographics and clinical practices. As with most retrospective analyses, causal inferences cannot be definitively established, and observed associations between iron parameters and outcomes may be influenced by unmeasured confounders. During dataset creation, some inflammatory markers were not routinely measured, making it difficult to distinguish between true iron overload and ferritin elevations driven by inflammation. Inflammation was partially assessed, as neutrophil count was initially measured, but interpreted to have no significant influence. Addressing this gap in future investigations could provide a clearer understanding of inflammatory mechanisms in iron dysregulation and heart failure progression.

Future Directions

The need for prospective validation of these findings should be emphasized, stratifying patients into nuanced ferritin–TSAT categories and testing personalized iron therapies. The analysis includes large numbers of patients and uses multiple adjustment models that incorporate age, shock, malignancy, renal function, ejection fraction, and comedications, bolstering that iron status itself is an independent risk factor. By comparing guideline-defined iron deficiency, TSAT-based regression, ferritin-based categories, and a combined Ferritin–TSAT model, the study gives a comprehensive perspective on how best to capture diverse risk groups in CHF. However, incorporating dedicated inflammatory biomarkers (CRP, hepcidin, soluble transferrin receptor [23]) would clarify whether hyperferritinemia is truly synonymous with iron repletion or driven by an acute-phase response that blocks normal iron utilization. Tracking iron indices beyond a single time point may also show how dynamic changes in iron status correlate with readmissions or advanced interventions for CHF. In turn, guidelines committees might adopt broader screening criteria that identify not only classical deficiency but also potential hyperferritinemic or inflammatory states.

Conclusion

This study reaffirms iron status—both extremely low and excessively high—as a central determinant of CHF outcomes. While guideline-defined iron deficiency remains a strong, practical predictor of early and longer-term mortality, a significant proportion of patients with ferritin ≥300 μg/L may also exhibit poor survival trajectories. Tertile-based models offer finer discrimination between true deficiency and hyperferritinemia, guiding either supplementation or further investigation of systemic drivers. Tailoring interventions based on iron parameters, such as prioritizing IV iron in deficiency or investigating inflammation in hyperferritinemia, exemplifies a precision-medicine approach to heart failure. By identifying iron misregulation early in the course of hospitalization, clinicians may optimize IV iron use, investigate inflammatory pathologies, and improve overall survival for patients grappling with CHF, although further trials are needed to define optimal timing and protocols.

Bibliography

1. Klip IT, Comin-Colet J, Voors AA, Ponikowski P, Enjuanes C, Banasiak W, Lok DJ, Rosentryt P, Torrens A, Polonski L, van Veldhuisen DJ, van der Meer P, Jankowska EA. Iron deficiency in chronic heart failure: an international pooled analysis. Am Heart J. 2013 Apr;165(4):575-582.e3. doi: 10.1016/j.ahj.2013.01.017. Epub 2013 Feb 22. PMID: 23537975.

2. Okonko DO, Mandal AK, Missouris CG, Poole-Wilson PA. Disordered iron homeostasis in chronic heart failure: prevalence, predictors, and relation to anemia, exercise capacity, and survival. J Am Coll Cardiol. 2011 Sep 13;58(12):1241-51. doi: 10.1016/j.jacc.2011.04.040. PMID: 21903058.

3. Martens P, Nijst P, Verbrugge FH, Smeets K, Dupont M, Mullens W. Impact of iron deficiency on exercise capacity and outcome in heart failure with reduced, mid-range and preserved ejection fraction. Acta Cardiol. 2018 Apr;73(2):115-123. doi: 10.1080/00015385.2017.1351239. Epub 2017 Jul 21. PMID: 28730869.

4. McDonagh T, Damy T, Doehner W, Lam CSP, Sindone A, van der Meer P, Cohen-Solal A, Kindermann I, Manito N, Pfister O, Pohjantähti-Maaroos H, Taylor J, Comin-Colet J. Screening, diagnosis and treatment of iron deficiency in chronic heart failure: putting the 2016 European Society of Cardiology heart failure guidelines into clinical practice. Eur J Heart Fail. 2018 Dec;20(12):1664-1672. doi: 10.1002/ejhf.1305. Epub 2018 Oct 12. PMID: 30311713; PMCID: PMC6607482.

5. Maidana D, Arroyo-Álvarez A, Barreres-Martín G, Arenas-Loriente A, Cepas-Guillen P, Brigolin Garofo RT, Caravaca-Pérez P, Bonanad C. Targeting Inflammation and Iron Deficiency in Heart Failure: A Focus on Older Adults. Biomedicines. 2025 Feb 13;13(2):462. doi: 10.3390/biomedicines13020462. PMID: 40002874; PMCID: PMC11853203.

6. Hentze MW, Muckenthaler MU, Galy B, Camaschella C. Two to tango: regulation of Mammalian iron metabolism. Cell. 2010 Jul 9;142(1):24-38. doi: 10.1016/j.cell.2010.06.028. PMID: 20603012.

7. Punj S, Ghafourian K, Ardehali H. Iron deficiency and supplementation in heart failure and chronic kidney disease. Mol Aspects Med. 2020 Oct;75:100873. doi: 10.1016/j.mam.2020.100873. Epub 2020 Aug 1. PMID: 32753256; PMCID: PMC7554149.

8. Jung HL. Absolute versus functional iron deficiency. Clin Exp Pediatr. 2025 Feb;68(2):138-140. doi: 10.3345/cep.2023.01732. Epub 2024 Nov 13. PMID: 39533727; PMCID: PMC11825113.

9. Anand IS, Gupta P. Anemia and Iron Deficiency in Heart Failure: Current Concepts and Emerging Therapies. Circulation. 2018 Jul 3;138(1):80-98. doi: 10.1161/CIRCULATIONAHA.118.030099. PMID: 29967232.

10. Sindone A, Doehner W, Manito N, McDonagh T, Cohen-Solal A, Damy T, Núñez J, Pfister O, van der Meer P, Comin-Colet J. Practical Guidance for Diagnosing and Treating Iron Deficiency in Patients with Heart Failure: Why, Who and How? J Clin Med. 2022 May 25;11(11):2976. doi: 10.3390/jcm11112976. PMID: 35683366; PMCID: PMC9181459.

11. Bhatia K, Sabharwal B, Gupta K, Lopez PD, Kaur A, Bhatia HK, Gandhi KD, Niroula S, Correa A, Birati EY, Argulian E, Fox A, Mahmood K. Clinical outcomes of intravenous iron therapy in patients with heart failure and iron deficiency: Meta-analysis and trial sequential analysis of randomized clinical trials. J Cardiol. 2024 Feb;83(2):105-112. doi: 10.1016/j.jjcc.2023.06.012. Epub 2023 Jun 26. PMID: 37380069.

12. Graham FJ, Pellicori P, Ford I, Petrie MC, Kalra PR, Cleland JGF. Intravenous iron for heart failure with evidence of iron deficiency: a meta-analysis of randomised trials. Clin Res Cardiol. 2021 Aug;110(8):1299-1307. doi: 10.1007/s00392-021-01837-8. Epub 2021 Mar 23. PMID: 33755777; PMCID: PMC8318946.

13. Ahmed M, Shafiq A, Javaid H, Singh P, Shahbaz H, Maniya MT, Jain H, Shakir N, Cheema HA, Ahmad A, Rehman WU, Yeap G, Nashwan AJ, Minhas AMK, Ahmed R, Fudim M, Fonarow GC. Intravenous iron therapy for heart failure and iron deficiency: An updated meta-analysis of randomized clinical trials. ESC Heart Fail. 2025 Feb;12(1):43-53. doi: 10.1002/ehf2.14905. Epub 2024 Jul 4. PMID: 38965691; PMCID: PMC11769671.

14. Beavers CJ, Ambrosy AP, Butler J, Davidson BT, Gale SE, Piña IL, Mastoris I, Reza N, Mentz RJ, Lewis GD. Iron Deficiency in Heart Failure: A Scientific Statement from the Heart Failure Society of America. J Card Fail. 2023 Jul;29(7):1059-1077. doi: 10.1016/j.cardfail.2023.03.025. Epub 2023 May 1. PMID: 37137386.

15. Packer M, Anker SD, Butler J, Cleland JGF, Kalra PR, Mentz RJ, Ponikowski P, Talha KM. Redefining Iron Deficiency in Patients With Chronic Heart Failure. Circulation. 2024 Jul 9;150(2):151-161. doi: 10.1161/CIRCULATIONAHA.124.068883. Epub 2024 May 11. PMID: 38733252; PMCID: PMC11224570.

16. Huang K, Altosaar J, Ranganath R. ClinicalBERT: Modeling Clinical Notes and Predicting Hospital Readmission. arXiv:190405342 [cs] [Internet]. 2019 Apr 11; Available from: https://arxiv.org/abs/1904.05342

17. Kocyigit, D, Kadri MG. Iron Deficiency and Its Treatment in Heart Failure: Indications and Effect on Prognosis. e-Journal of Cardiology Practice, vol. 14, no. 30, 21 Nov. 2016, https://www.escardio.org/Journals/E-Journal-of-Cardiology-Practice/Volume-14/Iron-deficiency-and-its-treatment-in-heart-failure-indications-and-effect-on-prognosis

18. Ponikowski P, Mentz RJ, Hernandez AF, Butler J, Khan MS, van Veldhuisen DJ, Roubert B, Blackman N, Friede T, Jankowska EA, Anker SD. Efficacy of ferric carboxymaltose in heart failure with iron deficiency: an individual patient data meta-analysis. Eur Heart J. 2023 Dec 21;44(48):5077-5091. doi: 10.1093/eurheartj/ehad586. PMID: 37632415; PMCID: PMC10733736.

19. Worwood M, May AM, Bain BJ. Iron deficiency anaemia and iron overload. In: Bain BJ, Bates I, Laffan MA, editors. Dacie and Lewis Practical Haematology. 12th ed. Philadelphia: Elsevier; 2017. p. 165–186.

20. Packer M, Anker SD, Butler J, Cleland JGF, Kalra PR, Mentz RJ, Ponikowski P, Talha KM. Redefining Iron Deficiency in Patients With Chronic Heart Failure. Circulation. 2024 Jul 9;150(2):151-161. doi: 10.1161/CIRCULATIONAHA.124.068883. Epub 2024 May 11. PMID: 38733252; PMCID: PMC11224570.

21. Zheng H, Cable R, Spencer B, Votto N, Katz SD. Iron stores and vascular function in voluntary blood donors. Arterioscler Thromb Vasc Biol. 2005 Aug;25(8):1577-83. doi: 10.1161/01.ATV.0000174126.28201.61. Epub 2005 Jun 16. PMID: 15961703.

22. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P; ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016 Jul 14;37(27):2129-2200. doi: 10.1093/eurheartj/ehw128. Epub 2016 May 20. Erratum in: Eur Heart J. 2018 Mar 7;39(10):860. doi: 10.1093/eurheartj/ehw383. PMID: 27206819.

23. Jankowska EA, von Haehling S, Anker SD, Macdougall IC, Ponikowski P. Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives. Eur Heart J. 2013 Mar;34(11):816-29. doi: 10.1093/eurheartj/ehs224. Epub 2012 Oct 25. PMID: 23100285; PMCID: PMC3596759.

24. Ciacciarelli A, Falcou A, Nicolini E, Broccolini A, Frisullo G, Abruzzese S, Scala I, Anticoli S, Testani E, Montinaro E, Ranchicchio C, De Michele M, Toni D. The prognostic role of iron deficiency in acute ischemic stroke patients: A prospective multicentric cohort study. J Neurol Sci. 2025 Feb 15;469:123371. doi: 10.1016/j.jns.2024.123371. Epub 2024 Dec 27. PMID: 39764913.

25. Mancardi D, Mezzanotte M, Arrigo E, Barinotti A, Roetto A. Iron Overload, Oxidative Stress, and Ferroptosis in the Failing Heart and Liver. Antioxidants (Basel). 2021 Nov 24;10(12):1864. doi: 10.3390/antiox10121864. PMID: 34942967; PMCID: PMC8698778.

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

	Guidelines-based Model (4.356, 95%CI 3.349–5.338, p<0.001)	
	HR	CI
Age	1.036	95%CI 1.03-1.05, p<0.001
Gender	1.105	95%CI 0.92-1.34, p=0.299
Mildly-Reduced Ejection Fraction	0.788	95%CI 0.51-1.24, p=0.299
Preserved Ejection Fraction	0.887	95%CI 0.74-1.08, p=0.212
ICU Stay	1.480	95%CI 1.19-1.86, p=0.001
Coronary Artery Disease	2.126	95%CI 1.18-3.84, p=0.012
Hypertension	1.130	95%CI 0.87-1.48, p=0.374
Shock	1.978	95%CI 1.53-2.56, p<0.001
Diabetes	1.496	95%CI 1.24-1.81, p<0.001
Malignant Cancer	1.501	95%CI 1.14-1.98, p=0.004
Hemoglobin (log10)	0.687	95%CI 0.25-1.95, p=0.48
eGFR (log10)	0.738	95%CI 0.52-1.07, p=0.101
History of CABG	0.314	95%CI 0.14-0.72, p=0.005
History of PCI	0.653	95%CI 0.40-1.08, p=0.097
ACE/ARB Use	0.684	95%CI 0.56-0.84, p<0.001
Dialysis Status	0.471	95%CI 0.33-0.68, p<0.001
IV Iron Supplementation	0.571	95%CI 0.45-0.73, p<0.001
Beta-Blocker Use	0.659	95%CI 0.53-0.82, p<0.001
Calcium Channel Blocker Use	0.673	95%CI 0.53-0.87, p=0.002

Table S1. Fully adjusted hazard ratios and confidence intervals for covariates with the Guidelines-based Model.

	TSAT Category Model (Tertile 2: 0.804, 95%CI 0.644–1.003, p=0.053 Tertile 3: 0.632, 95%CI 0.494–0.810, p<0.001)	
	HR	CI
Age	1.045	95%CI 1.04-1.05, p<0.001
Gender	1.275	95%CI 0.99-1.44, p=0.078
Mildly-Reduced Ejection Fraction	0.699	95%CI 0.50-1.23, p=0.278
Preserved Ejection Fraction	0.775	95%CI 0.67-0.99, p=0.031
ICU Stay	1.247	95%CI 1.15-1.80, p=0.002
Coronary Artery Disease	1.579	95%CI 0.85-2.75, p=0.159
Hypertension	1.179	95%CI 0.89-1.52, p=0.280
Shock	1.836	95%CI 1.40-2.34, p<0.001
Diabetes	1.560	95%CI 1.25-1.82, p<0.001
Malignant Cancer	1.398	95%CI 1.12-1.95, p=0.006
Hemoglobin (log10)	0.506	95%CI 0.21-1.72, p=0.340
eGFR (log10)	1.046	95%CI 0.55-1.14, p=0.209
History of CABG	0.255	95%CI 0.11-0.53, p<0.001
History of PCI	0.685	95%CI 0.37-1.00, p=0.050
ACE/ARB Use	0.685	95%CI 0.54-0.82, p<0.001
Dialysis Status	0.564	95%CI 0.34-0.69, p<0.001
IV Iron Supplementation	0.825	95%CI 0.54-0.87, p=0.002
Beta-Blocker Use	0.681	95%CI 0.53-0.82, p<0.001
Calcium Channel Blocker Use	0.684	95%CI 0.53-0.87, p=0.002

Table S2. Fully adjusted hazard ratios and confidence intervals for covariates with the TSAT Category Model.

	Ferritin Category Model (Tertile 2: 0.670, 95%CI 0.538–0.833, p<0.001 Tertile 3: 0.308, 95%CI 0.234–0.404, p<0.001)	
	HR	CI
Age	1.040	95%CI 1.04-1.05, p<0.001
Gender	1.186	95%CI 0.99-1.44, p=0.078
Mildly-Reduced Ejection Fraction	0.780	95%CI 0.50-1.23, p=0.278
Preserved Ejection Fraction	0.811	95%CI 0.67-0.99, p=0.031
ICU Stay	1.433	95%CI 1.15-1.80, p=0.002
Coronary Artery Disease	1.526	95%CI 0.85-2.75, p=0.159
Hypertension	1.160	95%CI 0.89-1.52, p=0.280
Shock	1.805	95%CI 1.40-2.34, p<0.001
Diabetes	1.507	95%CI 1.25-1.82, p<0.001
Malignant Cancer	1.472	95%CI 1.12-1.95, p=0.006
Hemoglobin (log10)	0.599	95%CI 0.21-1.72, p=0.340
eGFR (log10)	0.792	95%CI 0.55-1.14, p=0.209
History of CABG	0.231	95%CI 0.11-0.53, p<0.001
History of PCI	0.604	95%CI 0.37-1.00, p=0.050
ACE/ARB Use	0.661	95%CI 0.54-0.82, p<0.001
Dialysis Status	0.477	95%CI 0.34-0.69, p<0.001
IV Iron Supplementation	0.681	95%CI 0.54-0.87, p=0.002
Beta-Blocker Use	0.658	95%CI 0.53-0.82, p<0.001
Calcium Channel Blocker Use	0.674	95%CI 0.53-0.87, p=0.002

Table S3. Fully adjusted hazard ratios and confidence intervals for covariates with the Ferritin Category Model.

	Ferritin-TSAT Category Model (Tertile 2: 0.356, 95%CI 0.238–0.530, p<0.001 Tertile 3: 0.495, 95%CI 0.380–0.512, p<0.001)	
	HR	CI
Age	1.039	95%CI 1.03-1.05, p<0.001
Gender	1.191	95%CI 0.99-1.44, p=0.070
Mildly-Reduced Ejection Fraction	0.774	95%CI 0.50-1.22, p=0.262
Preserved Ejection Fraction	0.812	95%CI 0.68-0.99, p=0.031
ICU Stay	1.437	95%CI 1.15-1.80, p=0.002
Coronary Artery Disease	1.922	95%CI 1.06-3.50, p=0.032
Hypertension	1.163	95%CI 0.89-1.53, p=0.271
Shock	1.847	95%CI 1.43-2.40, p<0.001
Diabetes	1.488	95%CI 1.24-1.80, p<0.001
Malignant Cancer	1.474	95%CI 1.12-1.95, p=0.006
Hemoglobin (log10)	0.599	95%CI 0.21-1.72, p=0.340
eGFR (log10)	0.824	95%CI 0.58-1.19, p=0.295
History of CABG	0.224	95%CI 0.10-0.51, p<0.001
History of PCI	0.646	95%CI 0.39-1.08, p=0.090
ACE/ARB Use	0.683	95%CI 0.56-0.84, p<0.001
Dialysis Status	0.505	95%CI 0.36-0.73, p<0.001
IV Iron Supplementation	0.670	95%CI 0.53-0.86, p=0.001
Beta-Blocker Use	0.665	95%CI 0.54-0.83, p<0.001
Calcium Channel Blocker Use	0.682	95%CI 0.53-0.88, p=0.003

Table S4. Fully adjusted hazard ratios and confidence intervals for covariates with the Ferritin-TSAT Category Model.